Clinical Trials Logo

Metastatic Colorectal Cancer clinical trials

View clinical trials related to Metastatic Colorectal Cancer.

Filter by:

NCT ID: NCT05023720 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer

Start date: July 20, 2021
Phase:
Study type: Observational

Real-World Effectiveness of Regorafenib in the Treatment of Patients with Metastatic Colorectal Cancer- A Retrospective, Observational Study

NCT ID: NCT05016869 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Fruquintinib Plus Capecitabine as Maintenance Treatment of RAS / BRAF Wild-type Metastatic Colorectal Cancer

Start date: April 12, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II study was designed to evaluate the efficacy and safety of fruquintinib combination with capecitabine in maintenance treatment after first-line chemotherapy combined with cetuximab.

NCT ID: NCT05007132 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Trifluridine/ Tipiracil Plus Panitumumab Versus Trifluridine/ Tipiracil Plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer

Start date: December 17, 2021
Phase: Phase 2
Study type: Interventional

FIRE-8 is a prospective, randomized, open label, multicenter phase II clinical trial. To evaluate the effecacy of trifluridine / tipiracil and panitumumab (Arm A) compared to trifluridine / tipiracil and bevacizumab (Arm B), participants will be randomly assigned to either Arm A or Arm B for the treatment of metastatic colorectal cancer. The primary objectives of this study is to compare the effecacy of treatment with trifluridine / tipiracil plus panitumumab versus trifluridine / tipiracil plus bevacizumab.

NCT ID: NCT05004831 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Fruquintinib Combined With TAS-102 in the Treatment of Patients With Advanced Metastatic CRC

Start date: March 11, 2022
Phase: Phase 2
Study type: Interventional

This phase II study aims to explore the efficacy and safety of fruquintinib combined with TAS-102 in the third-line treatment of patients with advanced metastatic colorectal cancer.

NCT ID: NCT05004441 Recruiting - Clinical trials for Metastatic Colorectal Cancer

Fruquintinib Combined With mFOLFOX6/FOLFIRI in First-line Treatment for Metastatic Colorectal Cancer

Start date: July 22, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Fruquintinib Combined With mFOLFOX6/FOLFIRI as the first-line treatment of Metastatic Colorectal Cancer

NCT ID: NCT05004350 Active, not recruiting - Clinical trials for Metastatic Colorectal Cancer

A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.

NAUTICALCRC
Start date: September 14, 2021
Phase: Phase 2
Study type: Interventional

Encorafenib is currently being developed (with or without binimetinib), in combination with cetuximab, for the treatment of adult patients with B-RAF proto-oncogene, serine/threonine kinase V600E mutant (BRAF V600E) metastatic colorectal cancer (mCRC), who have received prior systemic therapy.

NCT ID: NCT04965870 Completed - Clinical trials for Metastatic Colorectal Cancer

A Study of Trifluridine/ Tipiracil in Chemorefractory mCRC in Greece

RETRO-TAS
Start date: June 30, 2021
Phase:
Study type: Observational

Collection of real world data on the clinical efficacy of trifluridine/ tipiracil (FTD/TPI) in the Greek population.

NCT ID: NCT04952753 Active, not recruiting - Clinical trials for Metastatic Colorectal Cancer

Study of NIS793 and Other Novel Investigational Combinations With SOC Anti-cancer Therapy for the 2L Treatment of mCRC

daNIS-3
Start date: November 15, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the preliminary efficacy and safety of NIS793 and other novel investigational combinations with standard of care (SOC) anti-cancer therapy vs SOC anti-cancer therapy for the second line treatment of mCRC. This study aims to explore whether different mechanisms of action may reverse resistance and improve responsiveness to the currently considered SOC anti-cancer therapy in the second line metastatic colorectal cancer (mCRC) setting.

NCT ID: NCT04948034 Recruiting - Clinical trials for Metastatic Colorectal Cancer

The Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE)

Start date: August 23, 2021
Phase: Phase 2
Study type: Interventional

This is a prospective, single-center, single-arm phase II clinical trial.This study aims to evaluate the safety and tolerability of stereotactic ablative radiotherapy (SABR) in combination with Fruquintinib and Tislelizumab, and to examine the impact of the combination therapy on tumor control, long-term survival and quality of life in patients with Metastatic colorectal cancer. A total of 68 metastatic colorectal cancer patients who have failed the first-line standard treatment, will be recruited and receive multisite SABR(8-12 Gy, 4-5 times) followed by fruquintinib(5mg, qd) and tislelizumab(200mg, q3w) within two weeks from completion.The overall response rate (ORR), disease control rate(DCR), progression-free survival(PFS) and overall survival(OS) will be analyzed.

NCT ID: NCT04929223 Active, not recruiting - Clinical trials for Metastatic Colorectal Cancer

A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Start date: October 22, 2021
Phase: Phase 1
Study type: Interventional

This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.